Your session is about to expire
← Back to Search
CAR T-cell Therapy
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Phase < 1
Recruiting
Research Sponsored by Zhejiang University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years after cd70 car-t cells infusion
Awards & highlights
No Placebo-Only Group
Summary
A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases
Eligible Conditions
- Multiple Myeloma
- Lymphoma
- Acute Myeloid Leukemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline up to 28 days after cd70 targeted car t-cells infusion
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to 28 days after cd70 targeted car t-cells infusion
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Dose-limiting toxicity (DLT)
Incidence of treatment-emergent adverse events (TEAEs)
Secondary study objectives
AML, Event-free survival (EFS)
AML, Overall survival (OS)
Activities of Daily Living (ADL) score
+10 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: T-NHLExperimental Treatment1 Intervention
Group II: T-ALLExperimental Treatment1 Intervention
Group III: AMLExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Zhejiang UniversityLead Sponsor
433 Previous Clinical Trials
4,123,420 Total Patients Enrolled
12 Trials studying Multiple Myeloma
637 Patients Enrolled for Multiple Myeloma
Yake Biotechnology Ltd.Industry Sponsor
33 Previous Clinical Trials
1,719 Total Patients Enrolled
9 Trials studying Multiple Myeloma
506 Patients Enrolled for Multiple Myeloma